STOCKHOLM, Nov. 6, 2020 /PRNewswire/ --
Third quarter
- Revenue amounted to €262.5m (€212.1m), an increase of 23.8%
with an organic growth of 12.3%.
- Operating profit (EBIT) was €27.3m (€14.3m), representing an
operating margin of 10.4% (6.7%).
- Net profit amounted to €19.5m (€6.3m), which represents a net
profit margin of 7.5% (3.0%).
- EBITDA was €50.1m (€32.5m), an increase of 54.4%. EBITDA margin
was 19.1% (15.3%).
- EBITDAaL amounted to €38.1m (€22.3m), corresponding to an
EBITDAaL margin of 14.5% (10.5%).
- Net cash flow from operating activities was €41.7m
(€22.6m).
- Basic/diluted earnings per share were €0.108 (€0.043).
- Covid-19 had a positive impact on operating performance.
Nine months
- Revenue amounted to €700.1m (€614.7m), an increase of 13.9%
with an organic growth of 4.7%.
- Operating profit (EBIT) was €31.4m (€35.7m), a decrease by
11.9%, representing an operating margin of 4.5% (5.8%).
- Net profit amounted to €8.5m (€18.1m), which represents a net
profit margin of 1.2% (2.9%).
- EBITDA was €104.4m (€87.3m), an increase of 19.6%. EBITDA
margin was 14.9% (14.2%).
- EBITDAaL amounted to €67.3m (€58.3m), an increase by 15.5%
corresponding to an EBITDAaL margin of 9.6% (9.5%).
- Net cash flow from operating activities was €116.5m
(€62.4m).
- Basic/diluted earnings per share were €0.054 (€0.120).
- Covid-19 had a cumulative negative impact on operating
performance.
- Directed share issue of 15 million shares completed in
June 2020, net proceeds of
€141.9m.
REVENUE AND EARNINGS
|
€ millions
(€m)
|
Q3
2020
|
Q3
2019
|
Variance
|
9M
2020
|
9M
2019
|
Variance
|
FY
2019
|
|
Revenue
|
262.5
|
212.1
|
24%
|
700.1
|
614.7
|
14%
|
844.4
|
|
Operating profit
(EBIT)
|
27.3
|
14.3
|
91%
|
31.4
|
35.7
|
-12%
|
46.5
|
|
Operating profit
margin
|
10.4%
|
6.7%
|
|
4.5%
|
5.8%
|
|
5.5%
|
|
Net profit
|
19.5
|
6.3
|
207%
|
8.5
|
18.1
|
-53%
|
24.7
|
|
Net profit
margin
|
7.5%
|
3.0%
|
|
1.2%
|
2.9%
|
|
2.9%
|
|
Basic/diluted
earnings per share, €
|
0.108
|
0.043
|
151%
|
0.054
|
0.120
|
-55%
|
0.168
|
|
|
|
|
|
|
|
|
|
EBITDA
|
50.1
|
32.5
|
54%
|
104.4
|
87.3
|
20%
|
120.7
|
|
EBITDA
margin
|
19.1%
|
15.3%
|
|
14.9%
|
14.2%
|
|
14.3%
|
|
EBITDAaL
|
38.1
|
22.3
|
71%
|
67.3
|
58.3
|
16%
|
80.6
|
|
EBITDAaL
margin
|
14.5%
|
10.5%
|
|
9.6%
|
9.5%
|
|
9.5%
|
|
EBITA
|
30.1
|
15.7
|
93%
|
44.2
|
39.8
|
11%
|
53.7
|
|
EBITA
margin
|
11.5%
|
7.4%
|
|
6.3%
|
6.5%
|
|
6.4%
|
Definition and reconciliation of alternative performance
measures are available at
www.medicover.com/financial-information.
This is information that Medicover AB is obliged to make public
pursuant to the EU Market Abuse Regulation and the Securities
Markets Act. The information was submitted for publication through
the agency of the contact person set out below at 7.45 (CET) on
6 November 2020. This interim report
and other information about Medicover is available at
medicover.com.
For further information, please contact:
Hanna Bjellquist, Head of
Investor Relations Phone:
+46-70-303-3272
hanna.bjellquist@medicover.com
Medicover is a leading international healthcare and diagnostic
services company and was founded in 1995. Medicover operates a
large number of ambulatory clinics, hospitals, specialty-care
facilities,laboratories and blood-drawing points and the
largest markets are Poland and
Germany. In 2019, Medicover had
revenue around €844 million and 28,800 employees. For more
information, go to
www.medicover.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medicover/r/interim-report-july-september-2020,c3232473
The following files are available for download:
|
https://mb.cision.com/Main/15662/3232473/1331462.pdf
|
Q3-report
2020
|
